MRK Stock Recent News
MRK LATEST HEADLINES
Merck (MRK) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MRK broke through the 20-day moving average, which suggests a short-term bullish trend.
Merck & Co., Inc. (NYSE:MRK ) BofA Securities 2024 Health Care Conference May 15, 2024 4:40 PM ET Company Participants Caroline Litchfield - EVP & CFO Conference Call Participants Geoff Meacham - Bank of America Securities Geoff Meacham [Call Starts abruptly] Caroline Litchfield, CFO. Caroline, good to see you.
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
Merck said on Monday it had discontinued the arm of a late-stage study, which tested an experimental antibody-based drug with its blockbuster immunotherapy Keytruda for some patients with the most severe form of skin cancer.
A commonly used strategy for investing is sector rotation. This involves the movement of funds from one sector to another based on macroeconomic and other factors.
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024.
Merck (MRK) shares advanced in intraday trading Thursday after the pharmaceutical firm reported better-than-expected quarterly results, and raised and narrowed its guidance on strong sales of its blockbuster cancer-fighting treatments.
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.